Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Table 1 Selected adjuvant or “strategy” (neoadjuvant vs adjuvant) clinical trials employing contemporary treatment regimens for resectable pancreatic adenocarcinoma

Study ID1	Design	Phase	Estimated accrual	Status
NCT00882310	Adjuvant Gem, Taxotere, and Xeloda	II	32	Active, not recruiting
NCT00960284	Post-operative Gemcitabine vs PEFG Followed by Chemoradiation	II/III	102	Completed
NCT01150630	Adjuvant Gem vs Adjuvant PEXG vs Neoadjuvant/Adjuvant PEXG	II/III	370	Recruiting
NCT01526135	Adjuvant Gem vs modified FOLFIRINOX2	III	490	Recruiting
NCT01660711	Neoadjuvant/Adjuvant modified FOLFIRINOX3	II	21	Recruiting
NCT01845805	Adjuvant nab-Paclitaxel/Gem/Azacitidine	II	80	Recruiting
NCT01964430	Adjuvant Gem vs nab-Paclitaxel/Gem (APACT)	III	800	Recruiting
NCT02023021	Adjuvant nab-Paclitaxel/Gem	II	80	Recruiting
NCT02047474	Neoadjuvant/Adjuvant modified FOLFIRINOX4	II	46	Recruiting
NCT02047513	Adjuvant only vs Neoadjuvant/Adjuvant nab-Paclitaxel/Gem (NEONAX)	RII5	166	Not yet recruiting
NCT02172976	Adjuvant Gemcitabine vs Neoadjuvant/Adjuvant FOLFIRINOX	II/III	126	Not yet recruiting

¹ClinicalTrials.gov Identifier;

²Oxaliplatin 85 mg/m², Irinotecan 165 mg/m², Leucovorin 400 mg/m², fluorouracil (5-FU) 2400 mg/m² c.i.v.i. over 48 h (no 5-FU bolus);

³Oxaliplatin 85 mg/m², Irinotecan 180 mg/m², Leucovorin 400 mg/m², 5-FU 2400 mg/m² c.i.v.i. over 48 h (no 5-FU bolus);

⁴Dose/schedule modifications not specified;

⁵Randomized phase II.